Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1630-1643

  Mackman, Richard L ^a   Sangi, Michael ^a   Sperandio, David ^a   Parrish, Jay P ^a   Eisenberg, Eugene ^a   Perron, Michel ^a   Hui, Hon ^a   Zhang, Lijun ^a   Siegel, Dustin ^a   Yang, Hai ^a   Saunders, Oliver ^a   Boojamra, Constantine ^a   Lee, Gary ^a   Samuel, Dharmaraj ^a   Babaoglu, Kerim ^a   Carey, Anne ^a   Gilbert, Brian E ^b   Piedra, Pedro A ^b   Strickley, Robert ^a   Iwata, Quynh ^a   Hayes, Jaclyn ^a   Stray, Kirsten ^a   Kinkade, April ^a   Theodore, Dorothy ^a   Jordan, Robert ^a   Desai, Manoj ^a   Cihlar, Tomas ^a   more..

^a GILEAD SCIENCES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GS 5806; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; ANTIVIRUS AGENT; GS-5806; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CANINE MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; EC50; HEP 2 CELL LINE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; ISOMER; LIVER CELL; LUNG PARENCHYMA; MONKEY MODEL; NONHUMAN; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; MACACA FASCICULARIS; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STRUCTURE ACTIVITY RELATION; VIROLOGY; VIRUS ENTRY;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; MACACA FASCICULARIS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PYRAZOLES; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; VIRUS INTERNALIZATION;

EID: 84923882231     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5017768     Document Type: Article

References (37)

1. Nair, H.; Nokes, J. D.; Gessner, B. D.; Dherani, M.; Madhi, S. A.; Singleton, R. J.; OBrien, K. L.; Roca, A.; Wright, P. F.; Bruce, N.; Chandran, A.; Theodoratou, E.; Sutanto, A.; Sedyaningsih, E. R.; Ngama, M.; Munywoki, P. K.; Kartasasmita, C.; Simòes, E. A. F.; Rudan, I.; Weber, M. W.; Campbell, H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 2010, 375 (9725) 1545-1555
2. Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L. J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the United States J. Am. Med. Assoc. 2003, 179-186
3. Blanken, M. O.; Rovers, M. M.; Molenaar, J. M.; Winkler-Seinstra, P. L.; Meijer, A.; Kimpen, J. L. L.; Bont, L. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants N. Engl. J. Med. 2013, 368, 1791-1799
4. Pérez-Yarza, E. G.; Moreno, A.; Lázaro, P.; Mejías, A.; Ramilo, O. The association between respiratory syncytial virus infection and the development of childhood asthma Pediatr, Infect. Dis. J. 2007, 26 (8) 733-739
5. Falsey, A. R.; Hennessey, P. A.; Formica, M. A.; Cox, C.; Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults N. Engl. J. Med. 2005, 352 (17) 1749-1759
6. Boeckh, M.; Englund, J.; Li, Y.; Miller, C.; Cross, A.; Fernandez, H.; Kuypers, J.; Kim, H.; Gnann, J.; Whitley, R. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients Clin. Infect. Dis. 2007, 44, 245-249
7. Committee on Infectious Diseases and Bronchiolitis Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014, 134, 415-420.
8. Ventre, K.; Randolph, A. G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. 2007, CD000181.pub2.
9. Najarro, P.; Angell, R.; Powell, K. The prophylaxis and treatment with antiviral agents of respiratory syncytial virus infections Antiviral Chem. Chemother. 2012, 22, 139-150
10. Welliver, R. C. Pharmacotherapy of respiratory syncytial virus infections Curr. Opin. Pharmacol. 2010, 10, 289-293
11. Olszewska, W.; Openshaw, P. Emerging drugs for respiratory syncytial virus infection Expert Opin. Emerging Drugs 2009, 14 (2) 207-217
12. Collins, P. L.; Melerob, J. A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years Virus Res. 2011, 162, 80-99
13. Henderson, E. A.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Budworth, J.; Carter, M. C.; Chubb, A.; Cockerill, S. G.; Dowdell, V. C. L.; Fraser, I. J.; Harris, R. A.; Keegan, S. J.; Kelsey, R. D.; Lumley, J. A.; Stables, J. N.; Weerasekera, N.; Wilson, L. J.; Powell, K. L. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate J. Med. Chem. 2007, 50, 1685-1692
14. Chapman, J.; Cockerill, S. G. Discovery and development of RSV604, Antiviral Drugs: From Basic Discovery Through Clinical Trials. John Wiley & Sons, Inc.: New York, 2011.
15. Sperandio, D.; Mackman, R. Respiratory syncytial virus fusion inhibitors. RSC Drug Discovery Series, Successful Strategies for the Discovery of Antiviral Drugs; Royal Society of Chemistry: Oxford, UK, 2013.
16. McKimm-Breschkin, J. VP-14637 Curr. Opin. Invest. Drugs 2000, 1 (4) 425-427
17. Changing the Way the World Takes Its Medicine; MicroDose Therapeutx: Monmouth Junction, NJ, 2009; www.mdtx.com (accessed December 20, 2014).
18. Teva R&D in Focus: Respiratory. Webinar Presentation, October 8, 2013; Teva Pharmaceutical Industries, Ltd.: Petach Tikva, Israel, 2013; www.tevapharm.com (accessed Dec 20, 2014).
19. DeVincenzo, J. P.; Whitley, R. J.; Mackman, R. L.; Scaglioni-Weinlich, C.; Harrison, L.; Farrell, E.; McBride, S.; Lambkin-Williams, R.; Jordan, R.; Xin, Y.; Ramanathan, S.; ORiordan, T.; Lewis, S. A.; Li, X.; Toback, S. L.; Lin, S.-L.; Chien, J. W. Oral GS-5806 activity in a respiratory syncytial virus challenge study N. Engl. J. Med. 2014, 371 (8) 711-722
20. Douglas, J. L.; Panis, M. L.; Ho, E.; Lin, K.-Y.; Krawcyzk, S. H.; Grant, D. M.; Cai, R.; Swaminathan, S.; Chen, X.; Cihlar, T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms Antimicrob. Agents Chemother. 2005, 49, 2460-1466
21. Bonfanti, C. M.; Doublet, F.; Fortin, J.; Muller, P.; Queguiner, L.; Gevers, T.; Janssens, P.; Szel, H.; Willebrords, R.; Timmerman, P.; Wuyts, K.; Remoortere, P. V.; Janssens, F.; Wigerinck, P.; Andries, K. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121) J. Med. Chem. 2008, 51, 875-896
22. Cianci, C.; Yu, K.-L.; Combrink, K.; Sin, N.; Pearce, B.; Wang, A.; Civiello, R.; Voss, S.; Luo, G.; Kadow, K.; Genovesi, E. V.; Venables, B.; Gulgeze, H.; Trehan, A.; James, J.; Lamb, L.; Medina, I.; Roach, J.; Yang, Z.; Zadjura, L.; Colonno, R.; Clark, J.; Meanwell, N.; Krystal, M. Orally active fusion inhibitor of respiratory syncytial virus Antimicrob. Agents Chemother. 2004, 48, 413-422
23. Anderson, K.; Andrau, L.; Bond, S.; Draffan, A.; Fenner, J.; Ji, H.; Iswaran, J.; Lambert, J.; Luttick, A.; Mayes, P.; McCarthy, M.; Lim, C. Y.; Lunniss, C.; Mitchell, J.; Morton, C.; Nearn, R.; Nguyen, V.; Patel, N.; Pitt, G.; Richter, B.; Ryan, J.; Sanford, V.; Suzich, J.; Tucker, S. Discovery and development of orally active antivirals for the treatment of RSV infections: Identification of BTA9881 as a clinical candidate. 7th International Respiratory Syncytial Virus Symposium, Rotterdam, The Netherlands, December 2-5, 2010.
24. Cambridge Crystallographic Data Centre; Cambridge Crystallographic Data Centre; www.ccdc.cam.ac.uk (accessed January 27, 2010).
25. Desai, P. V.; Raub, T. J.; Blanco, M.-J. How hydrogen bonds impact P-glycoprotein transport and permeability Bioorg. Med. Chem. Lett. 2012, 22, 6540-6548
26. Dalinger, I. L.; Vatsadse, I. A.; Shevelev, S. A.; Ivachtchenko, A. V. Liquid-phase synthesis of combinatorial libraries based on 7-trifluoromethyl-substituted pyrazolo[1,5- a ]pyrimidine scaffold J. Comb. Chem. 2005, 7, 236-245
27. Gavrin, L. K.; Lee, A.; Provencher, B. A.; Massefski, W. W.; Huhn, S. D.; Ciszewski, G. M.; Cole, D. C.; McKew, J. C. Synthesis of pyrazolo[1,5-α]pyrimidinone regioisomers J. Org. Chem. 2007, 72, 1043-1046
28. Mutlib, A. E.; Shockcor, J.; Chen, S.-Y.; Espina, R. J.; Pinto, D. J.; Orwat, M. J.; Prakash, S. R.; Gan, L.-S. Disposition of 1-[3-(aminomethyl)phenyl]- N -[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1 H -pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR Chem. Res. Toxicol. 2002, 15, 48-62
29. Bonfanti, J.-F.; Doublet, F.; Fortin, J.; Lacrampe, J.; Guillemont, J.; Muller, P.; Queguiner, L.; Arnoult, E.; Gevers, T.; Janssens, P.; Szel, H.; Willebrords, R.; Timmerman, P.; Wuyts, K.; Frans Janssens, F.; Sommen, C.; Wigerinck, P.; Andries, K. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship J. Med. Chem. 2007, 50, 4572-4584
30. Perron, M.; Stray, K.; Kinkade, A.; Theodore, D.; Lee, G.; Eisenberg, E.; Gilbert, B.; Jordan, R.; Piedra, P. A.; Mackman, R.; Cihlar, T. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates via a blockade of the virus fusion process. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 2-6, 2014, Poster V-1814.
31. Samuel, D.; Xing, W.; Niedziela-Majka, A.; Wong, J. S.; Stray, K. M.; Hung, M.; Brendza, K.; Perron, M.; Jordan, R.; Sperandio, D.; Liu, X.; Sakowicz, R.; Mackman, R. GS-5806 inhibits pre- to post-fusion conformational changes of the RSV fusion protein. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 2-6, 2014, Poster V-1807.
32. Roymans, D.; De Bondt, H. L.; Arnoult, E.; Geluykensa, P.; Gevers, T.; Ginderen, M. V.; Verheyen, N.; Kim, H.; Willebrords, R.; Bonfanti, J.-F.; Bruinzeel, W.; Cummings, M. D.; Vlijmen, H. V.; Andries, K. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 308-313
33. Marina, S.; Boukhvalova, M. S.; Prince, G. A.; Blanco, J. C. G. The cotton rat model of respiratory viral infections Biologicals 2009, 37, 152-159
34. Rouan, M.-C.; Gevers, T.; Roymans, D.; de Zwart, L.; Nauwelaers, D.; de Meulder, M.; van Remoortere, P.; Vanstockem, M.; Koul, A.; Simmen, K.; Andries, K. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model Antimicrob. Agents Chemother. 2010, 54, 4534-4539
35. Cianci, C.; Genovesi, E. V.; Lamb, L.; Medina, I.; Yang, Z.; Zadjura, L.; Yang, H.; DArienzo, C.; Sin, N.; Yu, K.-L.; Combrink, K.; Li, Z.; Colonno, R.; Meanwell, N.; Clark, J.; Krystal, M. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection Antimicrob. Agents Chemother. 2004, 48, 2448-2454
36. Jin, F.; Chien, J. W.; Mackman, R.; Lewis, S.; Bayly, S.; Ramanatha, S. Single and multiple dose-ranging evaluation of safety and pharmacokinetics of the RSV fusion inhibitor GS-5806. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 2-6, 2014, Poster A-009.
37. Xin, Y.; DeVincenzo, J. P.; Lewis, S. A.; Jin, F.; Swift, F.; Renton, N.; Mackman, R. L.; Jordan, R.; Toback, S. L.; Li, X.; Lin, S.-L.; Chien, J. W.; Ramanathan, S. Exposure-antiviral activity evaluation of GS-5806 in a RSV-challenge study in healthy subjects. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 2-6, 2014, Poster 72.